



FFG

Life Sciences im 7. RP

Astrid Hoebertz

Nationale Kontaktstelle für
Gesundheit 7. RP

Linz, 4. Juli 2011



Struktur und Budget 7. RP



FFG

COOPERATION – Kollaborative Forschung

Vordefinierte Themen, modifizierte "Instrumente"

32,4 Mrd €

IDEAS – Pionier Forschung

Individuelle Anträge, Europäischer Forschungsrat

7,5 Mrd €

PEOPLE – "Human Potential"

Mobilität von ForscherInnen

4,7 Mrd €

CAPACITIES – Forschungskapazitäten

Infrastruktur, KMU, Wissensregionen,...

4,1 Mrd €

Joint Research Center

1,7 Mrd €

+

EURATOM

50,5 Mrd €

1. Spezifisches Programm: Kooperation



COOPERATION – Collaborative research
Vordefinierte Themen und “Instrumente”

1. Gesundheit	6,1 Mrd €
2. Lebensmittel, Landwirtschaft, Fischerei, und Biotechnologie	1,9 Mrd €
3. Informations und Kommunikationstechnologien	9,0 Mrd €
4. Nano, Werkstoffe und Produktionstechnologien	3,4 Mrd €
5. Energie	2,3 Mrd €
6. Umwelt (einschliesslich Klimawandel)	1,9 Mrd €
7. Verkehr (einschliesslich Luftfahrt)	4,1 Mrd €
8. Sozial-, Wirtschafts- und Geisteswissenschaften	0,6 Mrd €
9. Weltraum	1,4 Mrd €
10. Sicherheit	1,4 Mrd €

7. RP Thema 1: Gesundheit (6,1 Mrd. Euro)



Ziele:

- Verbesserung der Gesundheit der europäischen Bevölkerung
- Stärkung der europ. Industrie/Firmen im Bereich Gesundheit
- Blick auf globale Gesundheitsfragen (z.B. Epidemien)




Fokus:

- **Translationale Forschung** (*basic research* → *clinical application*)
- Neue **Therapien** (Entwicklung und Validierung)
- Diagnostische **Instrumente**, medizinische **Technologien**
- Effiziente **Gesundheitssysteme**

=> Im Thema Gesundheit unterstützt 7. RP Grundlagen- und angewandte kollaborative Forschung – inkl. klinische Studien

The Health Theme Three main activities (“pillars”)



Based on draft Orientation paper – please refer to final published Work Programme 2012



Collaborative research

across borders and other barriers

- **between countries:**
 - multinational consortia, with at least 3 partners from 27 EU Member States (**MS**) + 12 Associated Countries (**AC**)
 - researchers from **any country in the world** can participate, from industrialised countries and from developing countries.
- **between different types of organizations**
Public & private sector: universities, research centres, large companies, Small and medium-sized enterprises (SMEs), etc.
- **between disciplines:** multidisciplinary, translational research

Based on draft Orientation paper – please refer to final published Work Programme 2012



Collaborative research across borders and other barriers

- **between countries:**

→ At least 3 partners from the 27 EU Member States:

Austria, Belgium, Bulgaria, Czech Rep., Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, the United Kingdom.

→ or the 13 Associated Countries:

Albania, Bosnia-Herzegovina, Croatia, FYROM, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey and the Faroe Islands.

→ In addition, researchers from anywhere in the world can participate:

e.g.: Australia, Brazil, Canada, China, Egypt, India, Japan, Korea, Russia, South-Africa, USA, ...

and in many cases, can be funded.



Ausschreibungen zu Gesundheit im Überblick:



- 1x/Jahr wird von der EC eine Ausschreibung/Call in "Gesundheit" veröffentlicht

1. Call - Einreichfrist: April 2007; 637 Mio €
2. Call - Einreichfrist: Sept 2007; 549 Mio €
3. Call - Einreichfrist: Dez 2008; 591 Mio €
4. Call - Einreichfristen Okt 2009 – Feb 2010, 640 Mio €
5. Call - Einreichfristen Okt/Nov 2010 - Budget 680 Mio €

6. Call – Einreichfrist Sept/Okt 2011 - Budget ca. 650 Mio €

- Ausgeschriebene Themen, Gesamtbudget etc. stehen in einem sogenannten "Arbeitsprogramm/Workprogramme"
- Themen/Topics sind exakt vorgegeben, ebenso Projekttyp und damit Projektbudget

7. Rahmenprogramm

Cooperation



Theme 1: Health

- ↳ Pillar 2: Translating Research for Human Health
- ↳ Area 2.2: Research on Brain and related diseases, human development and ageing
- ↳ Area 2.2.2: Human development and ageing
- ↳ Topic HEALTH.2012.2.2.2-2: Investigator-driven clinical trials for optimisation of management of elderly patients with multiple diseases.

Beispiel Topictext

=> mit einem Projekt muss der gesamte Topictext abgedeckt werden!

HEALTH.2012.2.2.2.-2: Investigator-driven clinical trials for optimisation of management of elderly patients with multiple diseases. FP7-HEALTH-2012-INNOVATION-1.

The aim of the projects should be the comparison of outcomes of various treatment regimens for those diseases that are most common in elderly populations. Research will focus on drug therapy and other interventions for patients affected by and treated for multiple diseases. Studies should include the evaluation of efficacy and adverse events. Applicants must demonstrate that clinical trials are appropriately powered to produce statistically significant evidence. *Gender aspects and differences related to age groups, ethnicity and socio-economic status should be appropriately considered.* The clinical trials to be supported must be registered in a publicly accessible clinical trials registry. The applications must consider the relevant governance issues for clinical trials such as good clinical practice and respect of the appropriate international, European and national legislation and guidelines. Patient advocacy groups, which can contribute to the quality, feasibility and impact of clinical trials, should be involved where appropriate.

Beispiel Topictext

...Fortsetzung:

Funding scheme: SME-targeted Collaborative project (small or medium-scale focused research project)

One or more proposals can be selected.

Expected impact: Three main impacts are expected: treatments better suited to the needs of older people, lowering healthcare costs and engaging in the pre-normative setting of geriatric medicines.

Additional eligibility criteria:

The **requested EU contribution** per project shall not exceed EUR 6 000 000

Projects will only be selected for funding on the condition that the estimated EU contribution going to **SME(s)** is at least 15% of the total estimated EU contribution for the project as a whole.

Projekttypen (1)

Verbundprojekte – Collaborative projects – **klassische Forschungsprojekte**

- Ziel: neues Wissen, neue Produkte
- Forschung in unterschiedlich großen Konsortien – Größe abhängig vom Bereich und Forschungsgegenstand

1. Small or medium-scale focused research project

- Förderhöhe: maximal 3 Mio € (Medium: 6 Mio €) EC contribution / Projekt
- *ø 10 Partner*
- *meist 3 - 4 Jahre Laufzeit*

2. Large-scale integrating project

- Förderhöhe: maximal 12 Mio € EC contribution / Projekt
- *ø 18 Partner*
- *meist 4 – 5 Jahre Laufzeit*

Achtung:
Zahlen nur für HEALTH 7. RP

FFG

Projekttypen (2)



Unterstützungs- und Koordinierungsmaßnahmen –

Supporting Actions and Coordinating Actions

- Kombination oder einzelne Durchführung von Konferenzen, Studien, Analysen, Personalaustausch, Verbreitung von Ergebnissen, Netzwerkbildung... – keine Forschung!

1. Coordinating Action

- Förderhöhe: maximal 2 Mio € EC contribution / Projekt
- \varnothing 12 Partner
- meist 3 - 4 Jahre Laufzeit

2. Supporting Action

- Förderhöhe: maximal 0.5 Mio € EC contribution / Projekt
- \varnothing 6 Partner
- meist 2 – 3 Jahre Laufzeit

Achtung:
Zahlen nur für HEALTH 7. RP

Features of FP7 Health in 2012

- Indicative budget for 2012 calls: €650m (tbc)
- 2 "Health" calls:
 - FP7-HEALTH-2012-INNOVATION-1 (32 topics, €540m)
 - FP7-HEALTH-2012-INNOVATION-2 (3 topics, €108m)
 - FP7-2012-ERA-NET call (1 topic, €2m)
- ALL topics will have two-stage submission
- MOST topics (28/36) can have several projects funded

6. Ausschreibung: Eckdaten



- Vor-Veröffentlichung Orientation Paper: 10. Mai 2011
- Veröffentlichung: 20. Juli 2011

Alles zweistufig! (bis auf 1 ERANET Topic)

- Einreichfristen
 - 1. Stufe: 27. September oder 4. Oktober 2011
 - 2. Stufe: Dezember 2011 oder Februar 2012

Features of FP7 Health in 2012 & 2013

- fewer, more prominent priorities
i.e. more focus on fewer areas
- fewer, broader topics, two-stage submission-evaluation
- greater emphasis on innovation
 - especially through SME-targeted topics
 - and continued support of clinical trials
- emphasis on flexibility for consortium, duration & budget
- international cooperation with more strategic focus

Priorities of FP7 Health in 2012

Main priorities:

- **Ageing** will be the 1st priority in 2012 – budget ~€220m (incl. med. tech, biomarkers, clinical trials, co-morbidity, health services)
- **Medical technologies** – €160m
- **Rare diseases** – ~€100m
- **SME targeted actions:**
 - 3 topics: ≥50% EC contrib. to SMEs: €108m
 - 6 topics: ≥30% EC contrib. to SMEs: €180m
 - 6 topics: ≥15% EC contrib. to SMEs: €72mTotal: 15 topics (out of 36 topics) – €360m (~55%)

Total budget: €650m (some overlap between priorities & budgets)

Based on draft Orientation paper – please refer to final published Work Programme 2012



17

Challenge: SME relevant research (1)



„Promoting innovation by strengthening the links between academia and industry is driving force of this workprogramme“

- Broad, SME-targeted topics (almost 50% of topics)
- Minimum funding of 15% or 30% or 50% must go to SMEs
- Overall, 20-25% of call budget will go to SMEs

=> new technologies, new drugs, new therapies

Challenge: SME relevant research (2)



Call “SMEs for INNOVATION – FP7-HEALTH-INNOVATION-2”

Pilot initiative to stimulate innovation via enhanced SME participation

Special conditions:

- 3-5 partners, min. 50% of req. EU funding for SME(s)
- Restricted to SMEs from EU and Associated Countries
- max. 3 years
- The SME must have a leading role in the project
- Simplified application process: short project description
- Accelerated procedures for submission, evaluation & negotiation i.e.: earlier deadlines for 1st and 2nd stage submission.

Challenge: SME relevant research (3)



Call “SMEs for INNOVATION – FP7-HEALTH-INNOVATION-2”

Pilot initiative to stimulate innovation via enhanced SME participation

3 broad topics with a focus on medical technologies:

- 1.4-2: Medical technology for transplantation and bio-artificial organs
- 2.3.0-1: Diagnostics for infectious diseases (in humans)
- 2.4.5-1: Technological approaches to combating sensory impairment

Challenge: Clinical Trials



Aim:

Translating research into clinical practice

Different types of clinical trials,
e.g. investigator-driven, observational

Scope:

- specified in each topic, phases covered will depend on budget
- expected to be mostly phase II, but for details see specific topics and special instructions for clinical trials in orientation paper.

7. RP Thema 1: Gesundheit - Struktur

1

Biotechnology, generic tools and technologies for human health

- 1.1 High-throughput research
- 1.2 Detection, Diagnosis and Monitoring
- 1.3 Suitability, Safety, Efficacy of Therapies,
- 1.4 Innovative Therapeutic Approaches and Interventions

2

Translating research for human health

- 2.1 Large Scale data gathering and Systems biology
- 2.2 Brain and Related diseases, Human development and Ageing
- 2.3 Translational research in major infectious diseases
- 2.4 Translational research in other major diseases (Cancer, CVD, ...)

3

Optimising the delivery of health care to European Citizens

- 3.1 Translating results of clinical research outcome into clinical practice..
- 3.2 Quality, Efficiency and Solidarity of Healthcare Systems
- 3.3 Enhanced Health promotion and disease prevention
- 3.4 International Public Health & Health Systems

4

Other Actions across the Health Theme

- 4.1 Coordination and Support actions across the theme
- 4.2 Responding to EU policy needs

1

Biotechnology, generic tools and technologies for human health

1.2 Detection, Diagnosis and Monitoring

- Technologies with a view to patient group stratification for personalised medicine applications

1.4 Innovative therapeutic approaches and interventions

- Approaches to solid organ transplantation
- Medical technology for transplantation sector and bioartificial organs
- Stem cell based therapies in regenerative medicine (with Australia)
- Targeted nucleic acid delivery as innovative therapeutic or prophylactic approach

*1.1 High-throughput research + 1.3 Suitability, safety and efficacy of therapies
Closed*

2

Translating research for human health (1)

2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE SCALE DATA GATHERING, SYSTEMS BIOLOGY

2.1.1 Large Scale data gathering

2.1.1.1 – Omics for rare diseases

- Support for international rare disease research
- Clinical utility of –omics for better diagnosis of rare diseases
- Databases, biobanks and ‘clinical bio-informatics’ hub for rare diseases
- Validation of –omics-based biomarkers for diseases affecting the elderly
- Statistical methods for collection and analysis of –omics data

2.1.2 Systems biology

- Systems Medicine: SME-driven research
- Systems Medicine: for understanding complex human diseases

2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING

2.2.1 *Brain and related diseases* *closed*

2.2.2 Human development and ageing

- Integrative systems biology and comparative genomics for studying human ageing and age-related diseases
- Clinical trials for elderly patients with multiple diseases

2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES

2.3.0 Cross-cutting

- Diagnostics for infectious diseases

2.3.2 HIV, AIDS, malaria and tuberculosis

- Co-infection of HIV/Aids, malaria, tuberculosis and/or hepatitis
- Co-morbidity between infectious and non-communicable diseases
- Prevention and treatment for HIV/Aids, malaria and tuberculosis
- Low-cost interventions for disease control in resource poor settings

2.3.1 *Anti-microbial drug resistance including fungal pathogens*

2.3.3 *Potentially new and re-emerging epidemics*

2.3.4 *Neglected infectious diseases (NID)*

All closed

2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES**2.4.3 Diabetes and Obesity:**

- Innovative approaches to manage diabetes
- Clinical trials for type I diabetes

2.4.4 Rare diseases

- Preclinical and/or clinical development of substances with clear potential as orphan drugs
- Observational trials in rare diseases
- Best practice and knowledge sharing in the clinical management of rare diseases

2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES**2.4.5 Other chronic diseases**

- Technological approaches to combating sensory impairments
- Biomarkers and diagnostics for chronic inflammatory diseases of joint and/or digestive system

2.4.1 Cancer + 2.4.2 Cardiovascular Disease (CVD): closed

3

Optimising the delivery of health care to European Citizens

3.2 Quality, solidarity and sustainability of health systems

- Improving the organisation of health service delivery
- New methodologies for health technology assessment
- Social innovation for active and healthy ageing

3.4 International Public Health & Health Systems

- Health systems/services research in low and middle income countries

3.1 Translating clinical research into clinical practice ...

*3.3 Enhanced health promotion and disease prevention
closed*

4

Other Actions across the Health Theme

4.1. Coordination and Support Actions across the Theme

- Network to encourage knowledge transfer activity in FP-funded health research
- Training actions linked to IPR management and knowledge transfer
- Communicating benefits of European research to general public
- Preparing the future for health research and innovation
- Setting health-related goals beyond 2015

4.2 Responding to EU Policy Needs

Closed

Zweistufige Einreichung



First stage:

- proposal size limited to 6 pages
(5 pages max. on proposed research and expected impact
+1 page max. to describe consortium & financial resources)
- only the coordinator needs to complete the 'A forms'
- evaluation of 2 criteria only (S/T quality and Impact)
- Higher thresholds

Second stage:

- only coordinators of proposals passing Stage 1 will be invited to submit full proposals for Stage 2
- evaluation on all 3 criteria, independently from Stage 1
- Higher thresholds

Finden Sie Partner für Ihre Projekte:

www.fitforhealth.eu

The screenshot shows the homepage of the Fit for Health website. The header features the logo and the URL www.fitforhealth.eu. A navigation menu on the left includes links for Home, Fit for Health, About the Initiative, News, Events, Publications, Learn more, Contact, and Xtranet. The main content area is titled "Online Search Tool" with the subtext "Find your project partner!". Below this, there is a "Welcome to Fit for Health!" section with a detailed description of the initiative's purpose and services. A "User menu" on the right offers a login link. Further down, there are sections for "Latest News" and "Upcoming Events". At the bottom, there is a link to "Download the Fit for Health newsletter issue 2" and logos for FFG, the European Union, and the Austrian Research Promotion Agency.

Förderraten



Maximum reimbursement rates of eligible costs	Research & Technological Development	Demonstration Activities	Training Activities	Management of consortium	Other Activities
<ul style="list-style-type: none"> • University • Public Body • Secondary & higher education establishments • Research organisations (non-profit) 	75 %	50 %	100 %	100 %	100 %
<ul style="list-style-type: none"> • Small and Medium Enterprises (SMEs) 	75 %	50 %	100 %	100 %	100 %
<ul style="list-style-type: none"> • Industry • Research Organisations (profit-making) 	50 %	50 %	100 %	100 %	100 %

Informationen: <http://rp7.ffg.at/health>

The screenshot shows the website for the 7th Framework Programme (FFG 7) under the heading 'Europäisches Forschungsrahmenprogramm'. The main navigation includes 'Basisinformationen', 'Was wird gefördert', 'Services der FFG', and 'Das nächste RP'. The current page is 'Ausschreibungen' (Calls for Proposals) under the 'Gesundheit' (Health) category.

Ausschreibungen

Ausschreibungen im Bereich **Gesundheit** werden in der Regel einmal im Jahr von der Europäischen Kommission mit vordefinierten, spezifischen Forschungsthemen (je nach Ausschreibung zwischen 30-50 Themen) veröffentlicht, für die sich europäische multidisziplinäre Konsortien bewerben können. Zwischen Veröffentlichung der Ausschreibungen und Einreichfrist für die Projektanträge liegen meist mindestens 3 Monate.

6. Ausschreibung im Bereich Gesundheit

Die 6. Ausschreibung im Bereich **Gesundheit** des 7. EU-Rahmenprogramms wurde am 10. Mai von der Europäischen Kommission (EK) vor-veröffentlicht, und soll am 20. Juli 2011 offiziell veröffentlicht werden.

Achtung: am 9. Juni gab es ein Update der vor-veröffentlichten Version mit einigen kleineren Änderungen, sowie einem neuen Topic zu "Setting health-related development goals beyond 2015".

Bitte halten Sie sich immer an die letzte Version bei der Vorbereitung ihres Antrags!

Vorveröffentlichung: Das **Orientation Paper** zur 6. Ausschreibung (Version 9. Juni) mit allen inhaltlichen Details finden Sie hier:

→ [Orientation Paper](#)

Zum jetzigen Zeitpunkt sind nur die geplanten Themen veröffentlicht, aber noch keine weiteren Dokumente für die Antragsstellung. Bitte beachten Sie auch den Disclaimer der EK, dass geringfügige Änderungen im Ausschreibungstext noch möglich sind und das Dokument noch nicht rechtsverbindlich ist.

Eine Übersicht der vorgesehenen Themen der 6. Ausschreibung finden Sie hier:

→ [6. Ausschreibung Gesundheit](#)

Details und Einreichfristen dieser Ausschreibung

Alle Themen der diesjährigen Ausschreibung werden eine zweistufige Einreichung haben (einzige Ausnahme: 1 ERA-NET Thema wird einstufig sein).

Der Call ist in zwei Sub-Calls unterteilt:

Information/Kontakt Gesundheit



FFG-Homepage: <http://rp7.ffg.at/health>

Beratung und Kontakt:

Dr. Astrid Hoebertz, astrid.hoebertz@ffg.at

Tel: +43 5 77 55 4104

Gesundheitsforschung – Alternativen zum HEALTH Programm



- **Innovative Medicines Initiative (IMI)**
- **Thema 2: Lebensmittel, Landwirtschaft, Fischerei, und Biotechnologie**, z. B. Allergien, Adipositas, Lebensmittel und Gesundheit
- **Thema 3: Informations und Kommunikationstechnologie**, z. B. E-Health, medizinische IT-Anwendungen
- **Thema 4: Nano, Werkstoffe und Produktionstechnologien**, z. B. Tissue engineering
- **Thema 6: Umwelt**, z. B. Umwelt und Gesundheit
- **Thema 10: Sicherheit**
- **Forschung zugunsten von KMU – FP7 Kapazitäten**

IMI – Innovative Medicines Initiative

Innovative Medicines Initiative: Konzept und Ausblick auf die 4. Ausschreibung

Was ist IMI?



- Public Private Partnership zwischen Europ. Kommission und EFPIA (European Federation of Pharmaceutical Industries Association)
- Gemeinsames Forschungsprogramm
- Ziel: Stärkung der Wettbewerbsfähigkeit des europäischen pharmazeutischen/biomedizinischen Sektors
- Budget bis 2013: 2 Mrd. €
 - 1 Mrd. € aus Health Budget 7. RP
 - 1 Mrd. € in kind von EFPIA Unternehmen


Die Ziele der IMI




- Durch **neue Methoden** (tools, assays, screens) **bessere Vorhersagbarkeit** der Sicherheit und Effizienz von Arzneimitteln erreichen - „Modernisierung“
- kein Ziel: Entwicklung neuer Medikamente
- Vorwettbewerbliche Forschung
- Überwindung von 4 „Bottlenecks“
 - Prediction of Safety
 - Prediction of efficacy
 - Knowledge management
 - Education and Training



Einreichung Stufe 1:



Einreichung Stufe 2:



4. IMI-Ausschreibung



Scientific Priorities 2011 veröffentlicht

7 Topics in 3 Themenblöcken ("Clusters"):

- EU Medical Information System
- Chemistry, Manufacturing and Control
- Technology and Molecular Disease Understanding

Call-Eröffnung: Juni 2011

Deadline: Mitte Oktober 2011

4. IMI-Ausschreibung



Cluster A: EU Medical Information System

1. Building up a European Medical Information System to improve Healthcare and Facilitate Research
2. ETRIKS: European Translational Research Infrastructure & Knowledge Management Services

Cluster B: Chemistry, Manufacturing and Control

3. Delivery and Targeting Mechanisms for Biological Macromolecules
4. In Vivo Predictive Biopharmaceutics Tools for Oral Drug Delivery
5. Sustainable Chemistry - Delivering Medicines for the 21st Century

Cluster C: Technology and Molecular Disease Understanding

6. Human Induced Pluripotent Stem (HIPS) Cells for Drug Discovery and Safety Assessment
7. Understanding and Optimising Binding Kinetics in Drug Discovery

Information/Kontakt IMI



IMI- Webseiten:

FFG-Homepage: http://rp7.ffg.at/health_jti_imi

IMI-website: www.imi.europa.eu

Partnersuchplattform: www.imi-partnering.eu

Beratung und Kontakt:

Dr. Ylva Huber, ylva.huber@ffg.at

Tel: +43 5 77 55 4102

Thema 2: Food, Agriculture & Fisheries, and Biotechnology - KBBE



Thema 2: Food, Agriculture & Fisheries, and Biotechnology - **KBBE**

Ziele:

- Aufbau einer europäischen, „wissensbasierten Bio-Ökonomie“ (Knowledge-Based Bio-Economy [KBBE])
- Zusammenwirken aller „Stakeholder“ :
Basis für neue, „öko-effiziente“, wettbewerbsfähige, bio-basierte Produkte
- Bewältigung **sozialer und ökonomischer Herausforderungen:**
 - Hochqualitative Lebensmittel und nachhaltige Lebensmittelproduktion
 - Ernährungsbedingte Krankheiten
 - Tierische Infektionskrankheiten und Zoonosen
 - Nachhaltige Landwirtschaft, Fischerei und Klimawandel
 - Saubere Biomaterialien aus erneuerbaren Bioressourcen



6th Call Food, Agriculture & Fisheries, and Biotechnology

Call Identifier: FP7-KBBE-2012-6 einstufig

Call öffnet: 20. Juli 2011

Deadline: 15. November 2011

Budget: ~ 300 Mio €

Information: <http://rp7.ffg.at/fafb>



6th Call Food, Agriculture & Fisheries, and Biotechnology

Arbeitsprogramm 2012 – Ansatz und Hintergründe

- Sustainable primary production, mitigating and adapting to climate change
- Low Carbon and resource efficient industry
- Food security and safety for Europe and beyond
- Socially inclusive and healthy Europe
- „The Ocean of Tomorrow“



6th Call Food, Agriculture & Fisheries, and Biotechnology

Spezieller Fokus und Maßnahmen für:


KMU (Kleine und Mittlere Unternehmen) = SMEs

- Teilnahme erwünscht in allen Bereichen
- Spezielle Unterstützungsmaßnahmen
- 33 Spezielle Topics mit obligatorischer KMU Teilnahme → mindestens 10% - 35% und bei 2 Topics 75% der Förderung für die beteiligten KMU

6th Call Food, Agriculture & Fisheries, and Biotechnology



DRAFT



6th Call Food, Agriculture & Fisheries, and Biotechnology



Activity 2.1

Sustainable production and management of biological resources from land, forest and aquatic environment

27 Topics

seed testing, livestock farming, irrigation management, on-farm biodiversity, bio-effectors, vineyard management, forest products, aquaculture, fisheries management, animal health and reproduction, socio-economic research...

Beispiel Topics:

- *Precision technologies to improve irrigation management*
- *Boosting the translation of FP projects' results into innovative applications*

DRAFT

6th Call Food, Agriculture & Fisheries, and Biotechnology



Activity 2.2

Fork to farm: Food (including sea-food), health and well being

17 Topics

consumer, bioactive compounds, lifestyle, food waste, packaging, seafood, food safety, food allergies...

Beispiel Topics:

- *Exploitation of Framework Programme project results in food processing by SMEs*
- *Microbially safe water for human consumption*
- *Impact of lifestyle on well-being and diet-related disease*

DRAFT

6th Call Food, Agriculture & Fisheries, and Biotechnology



Activity 2.3

Life sciences, biotechnology and biochemistry for sustainable non-food products and processes

14 Topics

novel sources of biomass and bioproducts, standardization, bio-waste, biopolymers, oil spill disasters, waste water, GMO risk assessments

Beispiel Topics:

- *Improved water stress tolerance of crop plants*
- *Biotechnology for novel biopolymers*
- *Biotechnological waste water treatments and reuse in agronomical systems, India*

DRAFT

Information/Kontakt KBBE



FFG-Homepage: <http://rp7.ffg.at/fafb>

Beratung und Kontakt:

Dr. Rita Litauszky, rita.litauszky@ffg.at

Tel: +43 5 77 55 4106

Forschung zugunsten von KMU – Research for the benefit of SMEs

Forschung zugunsten von KMU (Research for SMEs)

Kriterien:

- Klares Nutzungspotenzial für KMU
- Auslagerung des Großteils von Forschungsleistungen (RTD)
- Demonstrationsaktivitäten bekommen größere Bedeutung (Richtwert 6%)
- Keine thematischen Schwerpunkte – bottom up

5. Ausschreibung:

Veröffentlichung: vorauss. 20. Juli 2011
Ende der Einreichfrist: vorauss. 6. Dezember 2010
Budget: rd. 145 Mio. Euro
Informationen: http://rp7.ffg.at/kmu_roadshow2011
http://rp7.ffg.at/kmu_ausschreibungen

Research for SMEs: Eckdaten



Research for SMEs	
Projektdauer	1 - 2 Jahre
Gesamtprojektkosten*	0.5 – 1.5 M€
Förderhöhe	ca. 75% der Gesamt-Projektkosten (abhängig von den beteiligten Organisations- typen und deren Projekt-Aktivitäten)
Aktivitäten	<ul style="list-style-type: none">- Forschung und Entwicklung- Demonstration (zB Validierung)- Management- Andere (Training, Verbreitung)
Partneranzahl	Min. 3 KMU + 2 RTD aus versch. MS/AS (Ø 5 – 10 Partner)

* F&E-Anteil der ForschungsdienstleisterInnen: "bulk of the project"

Quelle: Europäische Kommission

Information/Kontakt

Forschung zugunsten von KMU Life Sciences



FFG-Homepage: http://rp7.ffg.at/kmu_ausschreibungen

Beratung und Kontakt:

Dr. Ines Haberl, ines.haberl@ffg.at

Tel: +43 5 77 55 4103



Unterstützung auf hohem Niveau... Services und Support I



- Elektronische Services: **eNewsletter, umfangreiches FP7-Portal (<http://rp7.ffg.at>)**
- FFG Akademie: **maßgeschneiderte Trainings für jede Projektphase (http://rp7.ffg.at/ffg_eip_akademie)**
- Persönliche Beratung: **Check der Idee, Tipps & Tricks, Alternativen zur FP7-Förderung**
- Proposal Check: **Detaillierte Überprüfung von Proposals**

Unterstützung auf hohem Niveau... Services und Support II



- Partnersuche: **NCP Netzwerke, Kompetenzkataloge, Brokerages, individuelle Suche**
- Hintergrundinformationen und -dokumente
- Rechts- und Finanzberatung: **Unterstützung durch ExpertInnen während jeder Projektphase**
- Verwertung: **Technologietransfer und -verwertung über das Enterprise Europe Network**

Life Sciences Team FFG



Dr. Astrid Hoebertz
Nationale Kontaktstelle Gesundheit => **HEALTH FP7**
05 7755 4104
astrid.hoebertz@ffg.at



Dr. Ylva Huber
Expertin Gesundheit (v.a. **IMI**)
und **KBBE**
05 7755 4102
ylva.huber@ffg.at



Dr. Rita Litauszky
Nationale Kontaktstelle KBBE
05 7755 4106
rita.litauszky@ffg.at



Dr. Ines Haberl
Nationale Kontaktstelle KMU
05 7755 4103
ines.haberl@ffg.at

KonsulentInnen zu Ihrer Unterstützung



Nationale Kontaktstellen (NCPs) und ExpertInnen im EIP beraten und coachen Sie sehr gerne im gesamten Projektzyklus, von der Antragstellung bis zur Verwertung der Ergebnisse, **ABER..**



Sie suchen Unterstützung bei **der Ausarbeitung**
von Anträgen ?



FORSCHUNG WIRKT.

>> www.ffg.at



FFG

